Report Detail

Pharma & Healthcare Obsessive-Compulsive Disorder - Pipeline Review, H2 2019

  • RnM3727955
  • |
  • 05 September, 2019
  • |
  • Global
  • |
  • 55 Pages
  • |
  • Global Markets Direct
  • |
  • Pharma & Healthcare

Obsessive-Compulsive Disorder - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obsessive-Compulsive Disorder - Pipeline Review, H2 2019, provides an overview of the Obsessive-Compulsive Disorder (Central Nervous System) pipeline landscape.

Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Risk factor includes family history. Treatment includes antidepressants and psychiatric medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obsessive-Compulsive Disorder - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Obsessive-Compulsive Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Obsessive-Compulsive Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Obsessive-Compulsive Disorder - Overview

              Obsessive-Compulsive Disorder - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Pipeline by Universities/Institutes

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Obsessive-Compulsive Disorder - Therapeutics Assessment

                            Assessment by Target

                              Assessment by Mechanism of Action

                                Assessment by Route of Administration

                                  Assessment by Molecule Type

                                    Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development

                                      Addex Therapeutics Ltd

                                        Amorsa Therapeutics Inc

                                          Biogen Inc

                                            Biohaven Pharmaceutical Holding Company Ltd

                                              Cannabis Science Inc

                                                Omeros Corp

                                                  Obsessive-Compulsive Disorder - Drug Profiles

                                                    ADX-88178 - Drug Profile

                                                      Product Description

                                                        Mechanism Of Action

                                                          R&D Progress

                                                            CBISOCD-001 - Drug Profile

                                                              Product Description

                                                                Mechanism Of Action

                                                                  R&D Progress

                                                                    OMS-527 - Drug Profile

                                                                      Product Description

                                                                        Mechanism Of Action

                                                                          R&D Progress

                                                                            PECS-101 - Drug Profile

                                                                              Product Description

                                                                                Mechanism Of Action

                                                                                  R&D Progress

                                                                                    psilocybin - Drug Profile

                                                                                      Product Description

                                                                                        Mechanism Of Action

                                                                                          R&D Progress

                                                                                            rituximab - Drug Profile

                                                                                              Product Description

                                                                                                Mechanism Of Action

                                                                                                  R&D Progress

                                                                                                    SERx-480 - Drug Profile

                                                                                                      Product Description

                                                                                                        Mechanism Of Action

                                                                                                          R&D Progress

                                                                                                            Small Molecules to Antagonize GRIN2B for Autism and Obsessive Compulsive Disorders - Drug Profile

                                                                                                              Product Description

                                                                                                                Mechanism Of Action

                                                                                                                  R&D Progress

                                                                                                                    Small Molecules to Target NMDA Receptor for Obsessive Compulsive Disorder - Drug Profile

                                                                                                                      Product Description

                                                                                                                        Mechanism Of Action

                                                                                                                          R&D Progress

                                                                                                                            troriluzole hydrochloride - Drug Profile

                                                                                                                              Product Description

                                                                                                                                Mechanism Of Action

                                                                                                                                  R&D Progress

                                                                                                                                    Obsessive-Compulsive Disorder - Dormant Projects

                                                                                                                                      Obsessive-Compulsive Disorder - Discontinued Products

                                                                                                                                        Obsessive-Compulsive Disorder - Product Development Milestones

                                                                                                                                          Featured News & Press Releases

                                                                                                                                            Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction

                                                                                                                                              Appendix

                                                                                                                                                Methodology

                                                                                                                                                  Coverage

                                                                                                                                                    Secondary Research

                                                                                                                                                      Primary Research

                                                                                                                                                        Expert Panel Validation

                                                                                                                                                          Contact Us

                                                                                                                                                            Disclaimer

                                                                                                                                                            Summary:
                                                                                                                                                            Get latest Market Research Reports on Obsessive-Compulsive Disorder. Industry analysis & Market Report on Obsessive-Compulsive Disorder is a syndicated market report, published as Obsessive-Compulsive Disorder - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of Obsessive-Compulsive Disorder market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                            Last updated on

                                                                                                                                                            REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                            Purchase this Report

                                                                                                                                                            $2,000.00
                                                                                                                                                            $4,000.00
                                                                                                                                                            $6,000.00
                                                                                                                                                            1,584.00
                                                                                                                                                            3,168.00
                                                                                                                                                            4,752.00
                                                                                                                                                            1,848.00
                                                                                                                                                            3,696.00
                                                                                                                                                            5,544.00
                                                                                                                                                            302,580.00
                                                                                                                                                            605,160.00
                                                                                                                                                            907,740.00
                                                                                                                                                            166,740.00
                                                                                                                                                            333,480.00
                                                                                                                                                            500,220.00
                                                                                                                                                            Credit card Logo

                                                                                                                                                            Related Reports


                                                                                                                                                            Reason to Buy

                                                                                                                                                            Request for Sample of this report